Business Context and Reporting Period
Company: SciSparc Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: August 2024 (Report No. 7)
Date Filed: August 26, 2024
Principal Executive Offices: Tel Aviv, Israel
The filing serves to incorporate by reference a press release issued on August 23, 2024, regarding the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The primary material event disclosed is the submission of an IND application to the FDA for the Company's candidate drug, SCI-110. This application is for a Phase IIb clinical trial targeting patients with Tourette Syndrome.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates specific paragraphs from the August 23, 2024 press release, including a section titled "Forward-Looking Statements," into the Company's registration statements on Form F-3 and Form S-8.
Risks and Contingencies: The filing references forward-looking statements but does not detail specific risks within the body of the Form 6-K text itself; investors are directed to the incorporated press release for these details.
Investor Verification Checklist
- Verify the status of the FDA's review of the IND application for SCI-110.
- Review the full text of the August 23, 2024 press release (Exhibit 99.1) for detailed forward-looking statements and risk factors.
- Confirm the timeline for the initiation of the Phase IIb clinical trial for Tourette Syndrome.
- Check subsequent filings for any updates on the FDA's decision regarding the IND application.